AstraZeneca

AstraZeneca· Business · 11 sources · Sep 28, 2026Story

AstraZeneca invests $2 billion in Summit cancer drug partnership

AstraZeneca will invest $2 billion in Summit Therapeutics convertible preferred shares, with Summit stock up more than 17% after-hours ahead of a November 14 FDA decision on ivonescimab.

Business· Sep 28, 2026

+1

AstraZeneca· Health · 10 sources · Sep 25, 2026Story

Imfinzi Bladder Combo Wins FDA Priority Review

Up to half of muscle-invasive bladder cancer patients cannot take standard chemo. FDA gave Priority Review to AstraZeneca's IMFINZI-enfortumab combo for them; decision due Q4 2026.

Health· Sep 25, 2026

+2

AstraZeneca· Health · 10 sources · Sep 11, 2026Story

AstraZeneca Breast Cancer Trial Misses Key Goal

AstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial when added to standard therapy, despite an earlier ESR1 mutation–targeted approval and after-hours stock weakness. The broader trial that reached more patients failed, while a separate study in ESR1-mutant patients showed a meaningful benefit, underscoring a split outcome for the drug’s potential.

Health· Sep 11, 2026

+3

AstraZeneca· Health · 8 sources · Aug 17, 2026Story

AstraZeneca Ends Phase III Lung Cancer Trial

AstraZeneca reports a setback as its Phase III trial of volrustomig plus chemotherapy in PD-L1 negative metastatic non-small cell lung cancer is halted after an independent data review found it unlikely to meet primary endpoints, while another late-stage study in cervical cancer and other indications continues. In a positive contrast, AZN and partners SAFFRON showed that Tagrisso combined with Orpathys significantly improved progression-free and overall survival, underscoring a mixed near-term outlook but ongoing strength in its immuno-oncology pipeline.

Health· Aug 17, 2026

0

AstraZeneca· Health · 8 sources · Jul 23, 2026Story

EU Approves Etcamah in First-Line ER+ Breast Cancer

AstraZeneca’s Etcamah (camizestrant) won EU approval to be used with CDK4/6 inhibitors as a first-line treatment for ER-positive, HER2-negative advanced breast cancer in patients with ESR1 mutations, based on SERENA-6 trial results showing a 56% reduction in progression or death. The drug already has approvals in Japan, the UAE, and Saudi Arabia, with U.S. review ongoing and the EU decision highlighting its potential to expand AstraZeneca’s oncology footprint as it targets endocrine-resistant disease.

Health· Jul 23, 2026

0

AstraZeneca

AstraZeneca

AstraZeneca invests $2 billion in Summit cancer drug partnership

Imfinzi Bladder Combo Wins FDA Priority Review

AstraZeneca Breast Cancer Trial Misses Key Goal

AstraZeneca Ends Phase III Lung Cancer Trial

EU Approves Etcamah in First-Line ER+ Breast Cancer

AstraZeneca across IJR

Top members

AstraZeneca across IJR

Latest AstraZeneca news and discussion

AstraZeneca invests $2 billion in Summit cancer drug partnership

Imfinzi Bladder Combo Wins FDA Priority Review

AstraZeneca Breast Cancer Trial Misses Key Goal

AstraZeneca Ends Phase III Lung Cancer Trial

EU Approves Etcamah in First-Line ER+ Breast Cancer

AstraZeneca across IJR

Top members

AstraZeneca across IJR